Figure S6 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer

Authors:
Open Access
Publisher website
Google Scholar
Abstract
METTL3-mediated post-transcriptional m6A modification contributes to the activation of MYLK-AS1 in TKI resistance of NSCLC.